Infectious Diseases Pharmacy Specialty Review Course for Recertification + RECERT Assessment Package (Cert # L199172)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 05/29/2019
Content Release Date: 06/26/2019
Expiration Date: 12/17/2019
Activity Type: Application-based
CE Credits: 25 hours (BPS and ACPE)
Activity Fee: $475 (ASHP member); $675 (non-member)

Accreditation for Pharmacists

The American Society of Health-System Pharmacists and American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

 

Target Audience

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in infectious diseases.

Activity Overview

This course is intended for BCIDPs in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS) to provide an overview of recent standards and guidelines that specialists should be familiar with in practice. The course uses a case-based approach to discuss patient care issues. In this series, faculty will:

  • Review pertinent clinical topics and practice skills
  • List valuable resources for further self-study  

This online course consists of 15 activities (see table below) and provides up to 25 hours of continuing pharmacy education credit and/or recertification credit.

Recertification Credit*

Board certified pharmacists are eligible to receive up to 25 hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed.  You are allowed only one attempt to successfully complete this assessment.

This course is not intended for those preparing to take the BPS Infectious Diseases Pharmacy Specialty Examination for Certification. To prepare for the examination, please see courses here: http://elearning.ashp.org/catalog/ID-review   

These activities are part of the ASHP and ACCP professional development program for BCIDP recertification approved by the BPS. 

* Please note: Review Course for Recertification may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle

 

 

Learning Activity

ACPE Number

Credit

Hours

*Assessment Pass Point

Infectious Diseases Pharmacy Specialty Review Course: Antimicrobial Stewardship

0204-9999-19-959-H01-P

1.50

72%

Infectious Diseases Pharmacy Specialty Review Course: Upper Respiratory Tract Infections

0204-9999-19-969-H01-P

2.00

Infectious Diseases Pharmacy Specialty Review Course: Lower Respiratory Tract Infections

0204-9999-19-966-H01-P

1.50

Group 1 Assessment

5.00

 

Infectious Diseases Pharmacy Specialty Review Course: HIV Infection and AIDS

0204-9999-19-972-H02-P

2.00

76%

Infectious Diseases Pharmacy Specialty Review Course: Infections of Reproductive Organs and Sexually-Transmitted Diseases

0204-9999-19-965-H01-P

1.50

Infectious Diseases Pharmacy Specialty Review Course: Opportunistic Infections in Immunocompromised Patients

0204-9999-19-960-H01-P

1.50

Group 2 Assessment

5.00

 

Infectious Diseases Pharmacy Specialty Review Course: Gastrointestinal and Intra-abdominal Infections

0204-9999-19-964-H01-P

1.50

72%

Infectious Diseases Pharmacy Specialty Review Course: Viral Hepatitis

0204-9999-19-971-H01-P

2.00

Infectious Diseases Pharmacy Specialty Review Course: Tuberculosis and Other Mycobacterial Infections

0204-9999-19-968-H01-P

1.50

 

Group 3 Assessment

5.00

 

Infectious Diseases Pharmacy Specialty Review Course: Cardiovascular Infections

0204-9999-19-961-H01-P

1.50

72%

Infectious Diseases Pharmacy Specialty Review Course: Urinary Tract Infections

0204-9999-19-970-H01-P

1.50

Statistics, Evidence-based Medicine, and Research Design

0204-9999-19-908-H04-P

2.00

Group 4 Assessment

5.00

 

Infectious Diseases Pharmacy Specialty Review Course: Bone and Joint Infections and Skin and Soft Tissue Infections

0204-9999-19-967-H01-P

1.50

76%

Infectious Diseases Pharmacy Specialty Review Course: Central Nervous System Infections

0204-9999-19-962-H01-P

1.50

Infectious Diseases Pharmacy Specialty Review Course: Clinical Microbiology

0204-9999-19-963-H01-P

2.00

Group 5 Assessment

5.00

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Learning Objectives

After participating in this CPE activity, leaners should be able to: 

Antimicrobial Stewardship
ACPE #0204-9999-19-959-H01-P

  • Outline components of an effective stewardship program.
  • Select appropriate resources; relevant accreditation, legal, regulatory, and safety requirements; and quality metrics related to infectious diseases.
  • Evaluate institutional treatment polices and pathways for compliance with antimicrobial stewardship guidelines, surveillance data, and best available evidence.
  • Assess the effectiveness of infection prevention and control strategies.
  • Identify metrics for evaluating the value of infectious disease pharmacy services. 

Upper Respiratory Tract Infections
ACPE #0204-9999-19-969-H01-P

  • Assess available pharmacotherapies for urinary tract infections.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease specific information, antibiogram data, and best available evidence.
  • Recommend appropriate modifications of patient‐specific treatment plans based efficacy and adverse effects.
  • Identify recommended immunizations and potential adverse effects. 

Lower Respiratory Tract Infections
ACPE #0204-9999-19-966-H01-P

  • Assess available pharmacotherapies for lower respiratory tract infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease specific information, antibiogram data, and best available evidence.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
  • Recommend the most appropriate modifications of patient‐specific treatment plans based on efficacy, adverse effects, and follow‐up assessment.
  • Interpret biomedical literature with regard to study design and methodology, significance of reported data and conclusions, limitations, and applicability of study results to patients with lower respiratory tract infections. 

HIV Infection and AIDS
ACPE #0204-9999-19-972-H02-P

  • Assess available pharmacotherapies for HIV‐infection and AIDS, including opportunistic infections.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease specific information, antibiogram data, and best available evidence.
  • Identify recommended immunizations and screening guidelines for patients with HIV.
  • Recommend appropriate modifications of patient‐specific treatment plans based on efficacy, drug interactions, immunologic response, and adverse effects.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results related to HIV infection.
  • Evaluate a plan to facilitate transitions of care. 

Infections of Reproductive Organs and Sexually-Transmitted Diseases
ACPE #0204-9999-19-965-H01-P

  • Assess available pharmacotherapies for infections of reproductive organs and sexually‐transmitted diseases.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease specific information, antibiogram data, and best available evidence.
  • Identify recommended screening guidelines for sexually‐transmitted diseases.
  • Recommend appropriate modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
  • Outline key considerations in effective patient and caregiver education and counseling techniques. 

Opportunistic Infections in Immunocompromised Patients
ACPE #0204-9999-19-960-H01-P

  • Assess the advantages and disadvantages of available pharmacotherapies for opportunistic infections in immunocompromised patients, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease specific information, antibiogram data, and best available evidence.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
  • Recommend appropriate modifications of patient‐specific pharmacotherapeutic plans based on efficacy, immunologic response, and adverse effects.
  • Identify preventative therapies in immunocompromised patients. 

Gastrointestinal and Intra-abdominal Infections
ACPE #0204-9999-19-964-H01-P

  • Assess available pharmacotherapies for gastrointestinal and intra‐abdominal infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease specific information, antibiogram data, and best available evidence.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
  • Recommend appropriate modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects. 

Viral Hepatitis
ACPE #0204-9999-19-971-H01-P

  • Assess available pharmacotherapies for viral hepatitis, including relevant pharmacology and spectrum of activity.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease specific information, virus and genotype, and best available evidence.
  • Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
  • Recommend appropriate modifications of patient‐specific treatment plans based on efficacy, adverse effects, and drug interactions.
  • Outline key considerations in effective patient and caregiver education and counseling techniques.
  • Identify screening guidelines and preventive therapies for viral hepatitis. 

Tuberculosis and Other Mycobacterial Infections
ACPE #0204-9999-19-968-H01-P

  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease specific information, antibiogram data, and best available evidence.
  • Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
  • Recommend appropriate modifications of patient‐specific treatment plans based on efficacy, adverse effects, and drug interactions.
  • Outline key considerations in effective patient and caregiver education and counseling techniques.
  • Identify screening guidelines and preventive therapies for tuberculosis and other mycobacterial infections. 

Cardiovascular Infections
ACPE #0204-9999-19-961-H01-P

  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease specific information, antibiogram data, and best available evidence.
  • Identify drug‐related problems associated with the therapeutic plan.
  • Recommend appropriate modifications of patient‐specific pharmacotherapeutic plans based on efficacy and adverse effects.
  • Interpret biomedical literature with regard to study design and methodology, significance of reported data and conclusions, limitations, and applicability of study results to patients with cardiovascular infections. 

Urinary Tract Infections
ACPE #0204-9999-19-970-H01-P

  • Assess available pharmacotherapies for lower respiratory tract infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease specific information, antibiogram data, and best available evidence.
  • Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
  • Identify infectious diseases for which notification of the Centers for Disease Control and Prevention is required. 

Statistics, Evidence-based Medicine, and Research Design
ACPE #0204-9999-19-908-H04-P

  • Given an excerpt from a study, determine quality and appropriateness of the excerpt, with specific attention to:
    • Study design
    • Statistical analysis
    • Internal/external validity
    • Sources of bias/confounders
    • Quality of conclusions
    • Interpretation of graphs from given studies
  • Determine clinical and statistical significance based on specified excerpts of studies
  • Determine why a statistical test is appropriate or not, given the sample distribution, data type, and study design
  • Interpret statistical significance for results from commonly used statistical tests
  • Describe the strengths and limitations of different types of measures of central tendency (mean, median, and mode) and data spread (standard deviation, standard error of the mean, range, and interquartile range)
  • Define and evaluate odds ratio (OR), risk/incidence rate, relative risk (RR), number needed to treat (NNT), number needed to harm (NNH), and other risk estimates
  • Determine whether the study applies to a specified patient population 

Bone and Joint Infections and Skin and Soft Tissue Infections
ACPE #0204-9999-19-967-H01-P

  • Assess the advantages and disadvantages of available pharmacotherapies for bone and joint infections and skin and soft tissue infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease specific information, antibiogram data, and best available evidence.
  • Identify drug‐related problems associated with the therapeutic plan.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
  • Recommend appropriate modifications of patient‐specific pharmacotherapeutic plans based on efficacy and adverse effects.
  • Describe the etiology, diagnosis, and treatment of acute bacterial osteomyelitis and septic arthritis in pediatric patients. 

Central Nervous System Infections
ACPE #0204-9999-19-962-H01-P

  • Assess available pharmacotherapies for central nervous system infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease specific information, antibiogram data, and best available evidence.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
  • Identify preventive therapies for central nervous system infections. 

Clinical Microbiology
ACPE #0204-9999-19-963-H01-P

  • Characterize the mechanisms of antimicrobial resistance among various pathogens.
  • Identify basic microbiology laboratory procedures.
  • Interpret laboratory and other diagnostic test results relevant to the diagnosis, management, and monitoring of patients with infectious diseases.
  • Evaluate biomedical literature with regard to study design and methodology specific to infectious diseases. 

Faculty

Samuel L. Aitken, Pharm.D., BCPS -AQ ID
Clinical Pharmacy Specialist - Infectious Diseases
The University of Texas MD Anderson Cancer Center
Houston, Texas 

Melissa Badowski, Pharm.D., M.P.H., BCPS, AAHIVP, FCCP
Clinical Associate Professor
University of Illinois at Chicago, College of Pharmacy
Chicago, Illinois 

Elizabeth A. Coyle, Pharm.D., BCPS, FCCM
Associate Dean for Academic Affairs and Clinical Professor
University of Houston College of Pharmacy
Houston, Texas 

Steven Ebert, B.S.Pharm., Pharm.D., FCCP, FIDSA
Clinical Pharmacy Manager, Infectious Diseases
UnityPoint Health-Meriter Hospital
Clinical Professor of Pharmacy
University of Wisconsin-MadisonMadison, Wisconsin 

Kevin W. Garey, Pharm.D., M.S., FASHP*
Professor and Chair
University of Houston
Houston, Texas 

Julie Harting, Pharm.D.
Associate Professor, Clinical & Administrative Sciences
Sullivan University College of Pharmacy
Clinical Pharmacist Specialist, Infectious Disease
University Hospital
Louisville, Kentucky 

Angela Huang, Pharm.D., BCPS-AQ ID
Antimicrobial Stewardship Coordinator
Froedtert & The Medical College of Wisconsin
Milwaukee, Wisconsin 

Jerod Nagel, Pharm.D., BCPS-AQ ID*
Team Lead, Infectious Diseases & Antimicrobial Stewardship
University of Michigan Health System
Ann Arbor, Michigan 

J. Nicholas O'Donnell, Pharm.D., M.Sc., BCPS
Assistant Professor
Albany College of Pharmacy and Health Sciences
Albany, New York 

Natasha Pettit, Pharm.D., BCPS-AQ ID
Infectious Diseases Clinical Pharmacy Specialist
University of Chicago Medicine
Chicago, Illinois 

Jason J. Schafer, Pharm.D., M.P.H., BCPS-AQ ID, AAHIVP*
Associate Professor, Department of Pharmacy Practice
Jefferson College of Pharmacy, Thomas Jefferson University
Philadelphia, Pennsylvania 

Kyana D. Stewart, Pharm.D., M.S., BCPS
Clinical Pharmacy Specialist
Ochsner Medical Center
New Orleans, Louisiana 

Kayla R. Stover, Pharm.D., BCPS-AQ ID, FCCP, FIDSA*
Associate Professor
University of Mississippi School of Pharmacy
Jackson, Mississippi 

Marylee Worley, Pharm.D., BCPS
Assistant Professor
Nova Southeastern University College of Pharmacy
Fort Lauderdale, Florida 

Evan Zasowski, Pharm.D., M.P.H., BCPS
Assistant Professor
Touro University California College of Pharmacy
Vallejo, California 

*Content Matter Experts 

Reviewers

Kristi N. Hofer, Pharm.D.
Susan R. Dombrowski, M.S., R.Ph. 

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, American College of Clinical Pharmacy and American Society of Health-System Pharmacists require that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP education activities are qualified and selected by ASHP and ACCP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Angela Huang: Consultant, Shionogi; Research grant recipient and Consultant, Merck & Company
  • Jason J. Schafer: Advisory Board, Theratechnologies; Research grant recipient, Merck & Company
  • Samuel L. Aitken: Advisory board, Gram Negative Advisory Panel, Merck & Company
  • Kevin W. Garey: Research grant recipient, Merck & Company
  • All other planners, presenters, and reviewers of this session report no financial relationships relevant to this activity. 

Acknowledgment

ACCP and ASHP gratefully acknowledge the following faculty for Self-Assessment Questions adapted from the 2018 ACCP Updates in Therapeutics: Infectious Diseases Preparatory Review Course.

Bland CM, Bookstaver PB, Chahine EB, et al., eds. Updates in Therapeutics: Infectious Diseases Preparatory Review Course, 2018 ed. Lenexa, KS: American College of Clinical Pharmacy, 2018:473‐516.

Elias B. Chahine, Pharm.D., FCCP, BCPS-AQ ID
Associate Professor of Pharmacy Practice
Lloyd L. Gregory School of Pharmacy
Palm Beach Atlantic University
West Palm Beach, Florida

Jessica M. Cottreau, Pharm.D., BCPS
Associate Professor
Rosalind Franklin University of Medicine and Science
North Chicago, Illinois 

Spencer H. Durham, Pharm.D., BCPS-AQ ID
Assistant Clinical Professor, Pharmacy Practice
Auburn Univeristy Harrison School of Pharmacy
Auburn, Alabama 

Eric F. Egelund, Pharm.D., Ph.D., AAHIVE
Clinical Assistant Professor
Department of Pharmacotherapy and Translational Research
Infectious Disease Pharmacokinetics Laboratory
University of Florida
Jacksonville, Florida 

Alan E. Gross, Pharm.D., BCPS-AQ ID
Clinical Assistant Professor
Pharmacy Practice
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois  

E. Kelly Hester, Pharm.D., FCCP, BCPS, AAHIVP
Associate Clinical Professor
Department of Pharmacy Practice
Auburn University Harrison School of Pharmacy
Auburn, Alabama 

Katie J. Suda, Pharm.D., M.S.
Research Associate Professor
Pharmacy Systems; Outcomes and Policy Center Affiliate
Center for Pharmacoepidemiology and Pharmacoeconomic Research
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois 

Kevin M. Sowinski, Pharm.D., FCCP
Professor of Pharmacy Practice
Associate Head for Scholarship and Faculty Affairs, Department of Pharmacy Practice
Purdue University College of Pharmacy
West Lafayette, Indiana 

Kurt A. Wargo, Pharm.D., FCCP, BCPS
Regional Dean
Associate Professor of Pharmacy
Wingate University
Hendersonville Health Sciences Center
Hendersonville, North Carolina

Methods and CE Requirements

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

System Technical Requirements

Learning activities are delivered via your Web browser and Acrobat PDF. For all activities you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 

Development

These activities were developed by ASHP and ACCP. 

To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for Board Certification Examinations.